MIRM (Mirum Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MIRM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-09-03 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | — | — |
| 2026-09-03 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-08-19 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | — | — |
| 2026-08-12 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-08-11 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-08-05 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | — | — |
| 2026-07-08 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-07-08 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-07-02 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | — | — |
| 2026-06-18 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | — | — |
| 2026-06-17 | Patrick J Heron | Director | A | — | — |
| 2026-06-17 | Laurent Fischer | Director | A | — | — |
| 2026-06-17 | Laura Brege | Director | A | — | — |
| 2026-06-17 | William Fairey | Director | A | — | — |
| 2026-06-17 | Timothy P Walbert | Director | A | — | — |
| 2026-06-17 | Lon Cardon | Director | A | — | — |
| 2026-06-17 | Saira Ramasastry | Director | A | — | — |
| 2026-06-17 | MICHAEL G GREY | Director | A | — | — |
| 2026-06-09 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-06-08 | Peter Radovich | PRESIDENT AND COO | M | — | — |
| 2026-06-02 | Lon Cardon | Director | M | — | — |
| 2026-06-02 | Timothy P Walbert | Director | M | — | — |
| 2026-06-02 | Saira Ramasastry | Director | MIXED | — | — |
| 2026-06-02 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-06-02 | Laurent Fischer | Director | M | — | — |
| 2026-05-18 | Saira Ramasastry | Director | MIXED | — | — |
| 2026-04-16 | Saira Ramasastry | Director | MIXED | — | — |
| 2026-03-17 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-03-17 | Saira Ramasastry | Director | MIXED | — | — |
| 2026-03-17 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-03-17 | Peter Radovich | PRESIDENT AND COO | MIXED | — | — |
| 2026-03-17 | Joanne Quan | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-03-17 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | — | — |
| 2026-03-11 | Peter Radovich | PRESIDENT AND COO | M | — | — |
| 2026-02-17 | Saira Ramasastry | Director | MIXED | — | — |
| 2026-02-03 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2026-02-03 | Peter Radovich | PRESIDENT AND COO | Sell | — | — |
| 2026-02-03 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | — | — |
| 2026-01-30 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-01-30 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-01-30 | Joanne Quan | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-01-30 | Peter Radovich | PRESIDENT AND COO | A | — | — |
| 2026-01-30 | Jolanda Howe | SVP, GLOBAL CONTROLLER | A | — | — |
| 2026-01-27 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-01-27 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | — | — |
| 2026-01-27 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-01-27 | Peter Radovich | PRESIDENT AND COO | MIXED | — | — |
| 2026-01-27 | Patrick J Heron | Director | MIXED | — | — |
| 2026-01-23 | ERIC BJERKHOLT | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,186,243 | — |
| — | 10%+ Owner | 3,736,243 | — |
| — | 10%+ Owner | 3,736,243 | — |
| — | 10%+ Owner | 3,736,243 | — |
| — | 10%+ Owner | 3,736,243 | — |
| — | 10%+ Owner | 3,116,912 | — |
| — | 10%+ Owner | 2,186,243 | — |
| — | 10%+ Owner | 2,186,243 | — |
| — | 10%+ Owner | 2,186,243 | — |
| — | 10%+ Owner | 2,186,243 | — |
| — | 10%+ Owner | 1,870,147 | — |
| — | 10%+ Owner | 1,724,456 | — |
| — | 10%+ Owner | 1,704,244 | — |
| — | Director | 1,621,118 | — |
| — | 10%+ Owner | 1,558,456 | — |
| — | Director | 464,713 | — |
| — | CHIEF EXECUTIVE OFFICER | 403,628 | — |
| — | CHIEF DEVELOPMENT OFFICER | 105,372 | — |
| — | CHIEF SCIENTIFIC OFFICER | 102,406 | — |
| — | 10%+ Owner | 99,325 | — |
| — | Director | 93,750 | — |
| — | PRESIDENT AND COO | 57,260 | — |
| — | Chief Medical Officer | 45,838 | — |
| — | CHIEF FINANCIAL OFFICER | 44,745 | — |
| — | 10%+ Owner | 30,135 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MIRM quote page; the site-wide leaderboard is on the insider transactions hub.